← Back to Screener
Akari Therapeutics plc ADR (0.01 USD) (AKTX)
Price$15.07
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-22.60%
Price vs S&P 500 (4W)137.24%
VGM Score51.44
Market Capitalization$18.13M
All Metrics
Book Value / Share (Quarterly)$0.00
P/TBV (Annual)15.76x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)26.00%
EPS (TTM)$-0.01
10-Day Avg Trading Volume4.61M
EPS Excl Extra (TTM)$-0.01
EPS (Annual)$-0.00
ROI (Annual)-59.48%
Cash / Share (Quarterly)$0.00
ROA (Last FY)-36.12%
EBITD / Share (TTM)$-0.00
ROE (5Y Avg)-327.53%
Cash Flow / Share (Annual)$-0.00
P/B Ratio1.26x
P/B Ratio (Quarterly)0.41x
Net Income / Employee (Annual)$-3,459,600
Net Interest Coverage (TTM)-10.29x
ROA (TTM)-63.01%
EPS Incl Extra (Annual)$-0.00
Current Ratio (Annual)0.44x
Quick Ratio (Quarterly)0.21x
3-Month Avg Trading Volume0.54M
52-Week Price Return-70.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
52-Week High$55.60
EPS Excl Extra (Annual)$-0.00
Tangible BV CAGR (5Y)-44.65%
26-Week Price Return-11.21%
Quick Ratio (Annual)0.43x
13-Week Price Return58.40%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)0.27x
Enterprise Value$16.09M
Book Value / Share Growth (5Y)-55.29%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev543.38%
Net Income / Employee (TTM)$-5,609,600
ROE (Last FY)-61.06%
Net Interest Coverage (Annual)-10.29x
EPS Basic Excl Extra (Annual)$-0.00
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)0.00x
ROI (TTM)-116.68%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)-97.71%
Year-to-Date Return37.02%
5-Day Price Return-3.59%
EPS Normalized (Annual)$-0.00
ROA (5Y Avg)-116.59%
Month-to-Date Return-3.59%
Cash Flow / Share (TTM)$-15.64
EBITD / Share (Annual)$-0.00
ROI (5Y Avg)-324.94%
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)6.22x
P/B Ratio (Annual)0.31x
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)47.90%
Beta1.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-123.29%
52-Week Low$3.02
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.57est. -1.40
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.20
4.20
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AKTXAkari Therapeutics plc ADR (0.01 USD) | — | — | C | $15.07 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Akari Therapeutics develops next-generation antibody-drug conjugates (ADCs) utilizing proprietary cancer-targeting payloads designed to improve upon existing therapies. The company's lead candidate, AKTX-101, is a preclinical Trop2-targeting ADC addressing solid tumors including lung, breast, colon, and prostate cancers. Akari's novel payload approach aims to enhance both the efficacy and safety profiles of current ADC treatments.